Track topics on Twitter Track topics that are important to you
The deal combines Daiichi Sankyo’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Under the terms of the
The post Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC appeared first on Pharma Business review.
Original Article: Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADCNEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...